- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating Impact of RRMM Treatment on Patient Quality of Life
Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
Preserving quality of life is paramount when treating relapsed/refractory multiple myeloma (RRMM). Beyond managing acute toxicities from newer treatments like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, preventing long-term adverse events is crucial. Peripheral neuropathy, largely from bortezomib, remains highly problematic despite weekly subcutaneous dosing. Neuropathy harms day-to-day functioning, requires added medications, increases fall/fracture risks, etc. More vigilance is needed even for grade 1 neuropathy. Encouragingly, more trials now include quality of life and patient-reported outcomes to capture patient perspectives and drive change, like the shift from 12 days of high-dose dexamethasone to just 4 days.
Recent updates with idecabtagene vicleucel and CAR T-cell therapy also suggest quality of life benefits compared to other regimens with less frequent health care contact. As measures become more standardized, quality of life differences may further influence treatment selections. Anecdotally, patients report feeling better on CAR T-cell therapy with reduced trips, injections, and dexamethasone exposure. While balancing efficacy remains vital, optimizing quality of life is a key goal in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
